|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CAPRIN1 |
Gene summary for CAPRIN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CAPRIN1 | Gene ID | 4076 |
| Gene name | cell cycle associated protein 1 | |
| Gene Alias | GPIAP1 | |
| Cytomap | 11p13 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q14444 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4076 | CAPRIN1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.85e-04 | 4.44e-01 | 0.294 |
| 4076 | CAPRIN1 | A015-C-203 | Human | Colorectum | FAP | 5.32e-29 | -4.15e-01 | -0.1294 |
| 4076 | CAPRIN1 | A015-C-204 | Human | Colorectum | FAP | 7.39e-05 | -3.09e-01 | -0.0228 |
| 4076 | CAPRIN1 | A014-C-040 | Human | Colorectum | FAP | 9.86e-05 | -5.67e-01 | -0.1184 |
| 4076 | CAPRIN1 | A002-C-201 | Human | Colorectum | FAP | 7.27e-09 | -2.87e-01 | 0.0324 |
| 4076 | CAPRIN1 | A002-C-203 | Human | Colorectum | FAP | 2.36e-04 | -1.41e-01 | 0.2786 |
| 4076 | CAPRIN1 | A001-C-119 | Human | Colorectum | FAP | 4.03e-04 | -2.64e-01 | -0.1557 |
| 4076 | CAPRIN1 | A001-C-108 | Human | Colorectum | FAP | 1.45e-11 | -2.39e-01 | -0.0272 |
| 4076 | CAPRIN1 | A002-C-205 | Human | Colorectum | FAP | 9.68e-15 | -3.12e-01 | -0.1236 |
| 4076 | CAPRIN1 | A001-C-104 | Human | Colorectum | FAP | 1.01e-02 | -1.10e-01 | 0.0184 |
| 4076 | CAPRIN1 | A015-C-006 | Human | Colorectum | FAP | 1.17e-08 | -3.55e-01 | -0.0994 |
| 4076 | CAPRIN1 | A015-C-106 | Human | Colorectum | FAP | 1.26e-09 | -2.52e-01 | -0.0511 |
| 4076 | CAPRIN1 | A002-C-114 | Human | Colorectum | FAP | 1.12e-11 | -3.20e-01 | -0.1561 |
| 4076 | CAPRIN1 | A015-C-104 | Human | Colorectum | FAP | 7.26e-27 | -3.13e-01 | -0.1899 |
| 4076 | CAPRIN1 | A001-C-014 | Human | Colorectum | FAP | 7.92e-15 | -3.12e-01 | 0.0135 |
| 4076 | CAPRIN1 | A002-C-016 | Human | Colorectum | FAP | 6.21e-19 | -2.80e-01 | 0.0521 |
| 4076 | CAPRIN1 | A015-C-002 | Human | Colorectum | FAP | 2.14e-07 | -2.60e-01 | -0.0763 |
| 4076 | CAPRIN1 | A001-C-203 | Human | Colorectum | FAP | 8.20e-07 | -1.77e-01 | -0.0481 |
| 4076 | CAPRIN1 | A002-C-116 | Human | Colorectum | FAP | 2.14e-26 | -3.24e-01 | -0.0452 |
| 4076 | CAPRIN1 | A014-C-008 | Human | Colorectum | FAP | 5.82e-08 | -3.75e-01 | -0.191 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001097614 | Thyroid | ATC | positive regulation of neuron projection development | 82/6293 | 163/18723 | 7.43e-06 | 7.61e-05 | 82 |
| GO:005196221 | Thyroid | ATC | positive regulation of nervous system development | 126/6293 | 272/18723 | 8.17e-06 | 8.27e-05 | 126 |
| GO:006099815 | Thyroid | ATC | regulation of dendritic spine development | 36/6293 | 61/18723 | 4.10e-05 | 3.32e-04 | 36 |
| GO:010602716 | Thyroid | ATC | neuron projection organization | 50/6293 | 93/18723 | 4.87e-05 | 3.88e-04 | 50 |
| GO:004881315 | Thyroid | ATC | dendrite morphogenesis | 71/6293 | 146/18723 | 1.18e-04 | 8.38e-04 | 71 |
| GO:009706115 | Thyroid | ATC | dendritic spine organization | 45/6293 | 84/18723 | 1.27e-04 | 9.03e-04 | 45 |
| GO:003424923 | Thyroid | ATC | negative regulation of cellular amide metabolic process | 121/6293 | 273/18723 | 1.36e-04 | 9.57e-04 | 121 |
| GO:006099911 | Thyroid | ATC | positive regulation of dendritic spine development | 26/6293 | 42/18723 | 1.60e-04 | 1.10e-03 | 26 |
| GO:009917314 | Thyroid | ATC | postsynapse organization | 78/6293 | 168/18723 | 3.66e-04 | 2.26e-03 | 78 |
| GO:001714823 | Thyroid | ATC | negative regulation of translation | 107/6293 | 245/18723 | 6.17e-04 | 3.51e-03 | 107 |
| GO:006100114 | Thyroid | ATC | regulation of dendritic spine morphogenesis | 27/6293 | 47/18723 | 6.69e-04 | 3.77e-03 | 27 |
| GO:006099712 | Thyroid | ATC | dendritic spine morphogenesis | 33/6293 | 61/18723 | 7.76e-04 | 4.28e-03 | 33 |
| GO:006100311 | Thyroid | ATC | positive regulation of dendritic spine morphogenesis | 14/6293 | 20/18723 | 9.60e-04 | 5.13e-03 | 14 |
| GO:009917512 | Thyroid | ATC | regulation of postsynapse organization | 44/6293 | 90/18723 | 1.89e-03 | 9.27e-03 | 44 |
| GO:005077511 | Thyroid | ATC | positive regulation of dendrite morphogenesis | 20/6293 | 37/18723 | 8.24e-03 | 3.16e-02 | 20 |
| GO:005080712 | Thyroid | ATC | regulation of synapse organization | 87/6293 | 211/18723 | 1.20e-02 | 4.27e-02 | 87 |
| GO:005077312 | Thyroid | ATC | regulation of dendrite development | 46/6293 | 103/18723 | 1.26e-02 | 4.42e-02 | 46 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CAPRIN1 | SNV | Missense_Mutation | rs772325651 | c.1624C>G | p.Gln542Glu | p.Q542E | Q14444 | protein_coding | tolerated(0.23) | possibly_damaging(0.814) | TCGA-AO-A12H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| CAPRIN1 | SNV | Missense_Mutation | novel | c.233A>G | p.Tyr78Cys | p.Y78C | Q14444 | protein_coding | deleterious(0.01) | benign(0.014) | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| CAPRIN1 | SNV | Missense_Mutation | novel | c.253N>A | p.Gly85Arg | p.G85R | Q14444 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-LL-A5YP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| CAPRIN1 | SNV | Missense_Mutation | novel | c.1141N>A | p.Glu381Lys | p.E381K | Q14444 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| CAPRIN1 | SNV | Missense_Mutation | rs148571717 | c.1744N>G | p.Gln582Glu | p.Q582E | Q14444 | protein_coding | tolerated(0.44) | possibly_damaging(0.498) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| CAPRIN1 | SNV | Missense_Mutation | novel | c.395N>T | p.Arg132Leu | p.R132L | Q14444 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| CAPRIN1 | SNV | Missense_Mutation | c.370C>G | p.Gln124Glu | p.Q124E | Q14444 | protein_coding | tolerated(0.14) | probably_damaging(0.98) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CAPRIN1 | SNV | Missense_Mutation | c.418N>C | p.Glu140Gln | p.E140Q | Q14444 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CAPRIN1 | SNV | Missense_Mutation | c.2054N>A | p.Gly685Glu | p.G685E | Q14444 | protein_coding | deleterious(0) | possibly_damaging(0.617) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CAPRIN1 | SNV | Missense_Mutation | novel | c.1244C>G | p.Ser415Cys | p.S415C | Q14444 | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-VS-A8Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |